Diamyd Medical AB

Diamyd executes agreement with US National Institutes of Health for a type 1 diabetes trial

Diamyd Medical announced that it has executed a Clinical Trial Agreement with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for a planned clinical study with the Diamyd® GAD-alum diabetes vaccine in 126 new onset type 1 diabetes patients. The clinical study wi ... more

Diamyd Medical outlicences Gene to Neurologix for treatment of Parkinson's disease

Diamyd Medical AB has entered into a non-exclusive license agreement by which Neurologix, Inc., obtained rights to use the GAD65 molecule in its development of a therapeutic treatment for Parkinson's disease. Terms of the agreement include a license execution payment of US $500,000, annual ... more

Diamyd Medical appoints Protein Sciences for production of its lead therapeutic diabetes vaccine

Diamyd Medical AB announced that is has reached an agreement with Protein Sciences Corporation, a biopharmaceutical service company, for production of Diamyd(TM), its lead therapeutic diabetes vaccine. Under the terms of the agreement, Protein Sciences (PSC) will produce Diamyd Medical's le ... more

Diamyd Medical AB

Diamyd Medical is a life science company developing treatments for diabetes and its complications. The company’s furthest developed project is the GAD-based drug Diamyd® for autoimmune diabetes for which Phase III studies are planned. Diamyd® has demonstrated significant and positive result ... more